RxDoctor Payments Data

Richard Vangrouw, MD

Cardiovascular Disease · Batesville, ARNPI 1306827571

Payments from drug & device makers

$1,240in general payments, 2019–2025

Across 61 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$479
  • Medtronic$277
  • Pfizer$122
  • Novartis$67
  • Boston Scientific$53
  • Actelion Pharmaceuticals US, Inc.$42
  • plus $200 from 11 others

What the payments were for

  • Food & beverage$1,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,240 in reported general payments places this provider in the 25th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$140,667
Medicare patients
682
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban217$164,574
EntrestoSacubitril/Valsartan57$45,969
XareltoRivaroxaban40$29,751
Propafenone Hcl48$2,308
Dabigatran EtexilateDabigatran Etexilate Mesylate11$1,740
Metoprolol Succinate197$1,605
Amiodarone Hcl148$1,512
Flecainide Acetate37$1,501
SotalolSotalol Hcl103$1,289
Ranolazine ErRanolazine20$1,253
Isosorbide Mononitrate ErIsosorbide Mononitrate102$1,217
ClopidogrelClopidogrel Bisulfate135$990
Losartan Potassium89$721
Furosemide236$706
Metoprolol Tartrate136$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$164,574217 claims
NovartisEntresto$67$45,96957 claims
Johnson & JohnsonXarelto$17$29,75140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Batesville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →